Please share experience of venetoclax plus obi... - CLL Support

CLL Support

22,988 members39,473 posts

Please share experience of venetoclax plus obinutuzimab or acalabrutinib mono treatment in an important survey

Jm954 profile image
Jm954Administrator
14 Replies

Reminder - please complete the survey if you are any of the above treatments. At the moment we have only had a few responses.

By completing this survey you are part of the process that may help patients gain access to these treatments in lots of countries. Your experience as a patient is a vitally important part of this process.

The survey will be open until midnight Pacific Time on Friday, February 28th, 2020 and should only take 10 minutes of your time.

Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) monotherapy for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) monotherapy for treatment of relapsed or refractory CLL/SLL

Here is the link, it should take about 10 minutes.

On behalf of all patients, thank you!

surveymonkey.com/r/CLLCAN2020

Jackie

Written by
Jm954 profile image
Jm954
Administrator
To view profiles and participate in discussions please or .
Read more about...
14 Replies
UK-Sparky profile image
UK-Sparky

Have done, eazy todoand results are shared

Jm954 profile image
Jm954Administrator in reply to UK-Sparky

Thank you!

LovecuresCLL profile image
LovecuresCLL

I completed survey. Thanks I hope folks get the help they need

AdrianUK profile image
AdrianUK

I’m just wondering why there’s no comparator group for those of us who had FCR. Would it not be helpful to be able to contrast experiences?

Jm954 profile image
Jm954Administrator in reply to AdrianUK

Because this is a subjective survey of people's experiences with these treatments, not a trial of any sort.

The answers are helpful when completing Health Technology Appraisals and we can say things along the lines of "x% had no side effects at all from xxx". We can also say what were the challenges for patients, so complying with the guidelines for the V ramp up might put some people off and we like to know those things.

Jackie

Smakwater profile image
Smakwater

In the mix Jackie,

JM

budman549-USA profile image
budman549-USA

I completed the survey but frequently added comments that I am still receiving treatment as part of the AbbVie M16-788 study

Jm954 profile image
Jm954Administrator in reply to budman549-USA

Thank you, very grateful 😊

Jm954 profile image
Jm954Administrator

Still time to reply to the survey if you can. It would be appreciated.

Jackie

Etoile7 profile image
Etoile7

Hi Jackie, this sounds very interesting. when do you think results will be available and how can we access those, even if we have not been able to answer the survey (as not treated yet, for example)?

Jm954 profile image
Jm954Administrator in reply to Etoile7

This is being organised by CLL patient advocates in Canada so we are in their hands but yes, when we get the results, I’m sure we can share them.

Jackie

SethB34 profile image
SethB34

Were the results of this survey ever released?

Jm954 profile image
Jm954Administrator in reply to SethB34

It's still ongoing

SethB34 profile image
SethB34

Ok thanks.

Not what you're looking for?

You may also like...

Survey for CLL patients having taken Venetoclax or Acalabrutinib

CLL/SLL Patient Survey If you have CLL or SLL and have been treated with the following therapies,...

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent...

NICE Recommends Acalabrutinib for treating CLL for certain groups

NICE has approved Acalabrutinib as monotherapy and is recommended as an option for untreated...

Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL

Great news from this long awaited first published phase 2 study reporting the efficacy of this AVO...

Zanubrutinib-Gazyva Shows Promise for CLL/SLL

June 25, 2019 Zanubrutinib (BGB-3111) is an investigational small molecule inhibitor of Bruton’s...